MOHR MARSHALL 4

What Happened
Marshall Mohr, a director of Pacific Biosciences of California, Inc. (PACB), was granted a derivative award covering 223,492 shares on 2026-06-03. The award shows an acquisition price of $0.00 (i.e., a grant of a derivative instrument rather than a market purchase), so the reported cash value at grant is $0. This is a compensation-style grant rather than an open-market buy or sale.

Key Details

• Transaction date: 2026-06-03 (reported on Form 4 filed 2026-06-04).
• Transaction type/code: A — Grant / award / other acquisition (derivative).
• Shares/units granted: 223,492 (acquisition price reported as $0.00).
• Shares owned after transaction: Not specified in the filing provided.
• Vesting: Per footnote, the shares subject to the option will vest monthly over one year (on the same day of the month as the grant or sooner at the next annual meeting), contingent on continued service.
• Timeliness: Filing appears timely (transaction date 06-03-2026; Form 4 filed 06-04-2026).
• No 10b5-1 plan, tax-withholding, or cashless-sale details were disclosed in the provided filing.

Context
This is a common form of director compensation (a derivative/share-based award that vests over time) and does not necessarily indicate the director bought or sold stock in the open market. For retail investors, such grants are informative about executive/director compensation and potential future dilution when awards vest or are exercised, but they are not direct signals of immediate buying/selling intent.